Clinical Outcomes and Healthcare Cost and Resource Utilization (HCRU) in Patients With Type 2 Diabetes and Cardiovascular Disease on 2nd Line Empagliflozin Versus 2nd Line Sulfonylureas

NCT05102071 · clinicaltrials.gov ↗

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Study was canceled because database sample size was inadequate.

Conditions

Diabetes Mellitus, Type 2
Cardiovascular Diseases

Interventions

DRUG: empagliflozin
DRUG: metformin
DRUG: sulfonylurea

Sponsor

Boehringer Ingelheim